Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis

Body weight loss of ≥ 10% improves the metabolic derangements and liver disease in the majority of non-alcoholic steatohepatitis (NASH) patients, suggesting metabolic modulators may be effective in controlling disease. The pharmacodynamics of ALT-801, a GLP-1/glucagon receptor dual agonist optimized...

Descripción completa

Detalles Bibliográficos
Autores principales: Nestor, John J., Parkes, David, Feigh, Michael, Suschak, John J., Harris, M. Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035150/
https://www.ncbi.nlm.nih.gov/pubmed/35461369
http://dx.doi.org/10.1038/s41598-022-10577-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035150/
https://www.ncbi.nlm.nih.gov/pubmed/35461369
http://dx.doi.org/10.1038/s41598-022-10577-2

Ejemplares similares